VLP Selection and Production Guide for Vaccine and Antibody Research

Virus-like particles are noninfectious, self-assembled structures that resemble natural viruses without containing the genetic material required for replication. Their organized, repetitive antigen display can support strong immune recognition, making them valuable for vaccine development, immunization and antibody discovery.

This guide focuses on selecting and purchasing the right VLP format. Choose a VLP-displayed protein when your research requires a full-length membrane target, native-like extracellular epitopes or multivalent antigen presentation. Choose a soluble protein for accessible domains and routine binding assays, or consider a nanodisc when a smaller, controlled lipid environment is required. Beta LifeScience provides ready-to-use VLP-displayed transmembrane proteins and custom membrane protein production in VLPs for vaccine research, immunization and antibody-screening workflows.

Quick VLP Platform Selection Guide

Need help selecting a VLP format? Request a technical evaluation based on your target, application, species, quantity and validation requirements.

How Do Virus-Like Particles Mimic Pathogens?

Virus-like particles, or VLPs, reproduce the organized shape and surface presentation of natural viruses while lacking a complete viral genome. This makes them nonreplicating research platforms for presenting antigens in a dense, repetitive arrangement. Their structure can support B-cell recognition, uptake by dendritic cells and downstream T-cell responses. The resulting immunogenicity depends on antigen density, orientation, particle composition, expression host, formulation and experimental model.

For a buyer, the most important question is whether this pathogen-like presentation adds value to the intended study. VLPs are especially useful when soluble proteins provide limited representation of the target’s natural membrane-associated structure.

When Should You Choose a VLP?

A VLP is a strong choice when the project requires:

• Full-length membrane protein presentation
• Native-like extracellular epitopes
• Multivalent antigen display
• Animal immunization
• Hybridoma or B-cell screening
• Antibody discovery against conformational epitopes
• ELISA-based screening
• Vaccine candidate research
• Native-like transmembrane protein topology

VLP-displayed proteins are particularly useful for GPCRs, claudins, ion channels, transporters, immune receptors and viral envelope proteins. These targets often rely on a lipid environment for appropriate folding and surface presentation. A VLP may be less suitable when the workflow requires straightforward immobilization for conventional SPR or BLI. A soluble extracellular domain or a compatible nanodisc may provide a more convenient format for those applications.

Beta LifeScience’s existing VLP Membrane Protein Applications guide explains immunization, antibody development and membrane-protein applications in more detail. This selection guide focuses on choosing a format, reviewing product specifications and planning production.

Selecting a VLP for Vaccine Development

Virus-like particles are established vaccine technology platforms because they can display antigens in a pathogen-like arrangement while remaining noninfectious. Licensed vaccines based on VLP technology include products targeting hepatitis B virus and human papillomavirus.

For a research-stage VLP vaccine project, the purchasing and production decision should focus on:

• Desired antigen orientation
• Required antigen copy density
• Full-length protein versus selected domain
• Membrane-associated versus non-membrane antigen
• Preferred expression host
• Immunization quantity
• Endotoxin requirement
• Particle size and homogeneity
• Binding or activity validation
• Formulation and storage

A full-length VLP-displayed membrane protein may be valuable when native topology and extracellular loops are central to immune recognition. A domain-displayed VLP may be more suitable when the project focuses on a defined epitope or antigenic region.

Researchers should also determine whether they require a catalog product for immediate testing or custom VLP production for a new target, sequence or antigen configuration.

VLP Products for Antibody and Vaccine Research

Beta LifeScience’s catalog includes VLP-displayed oncology and immunology targets. Product specifications and availability vary, so researchers should review each datasheet and request current lot information before ordering.

Found a suitable catalog target? Review its species, sequence, expression host, purity method, endotoxin specification, activity data, storage instructions and current availability before placing an order.

VLPs vs Nanodiscs, Soluble Proteins and Detergent Systems

No single protein format is ideal for every experiment. The assay and required biological context should guide the selection.

Choose VLPs for native-like immunization.

A VLP is usually the strongest option when the project requires multivalent presentation of a full-length membrane protein for immunization, antibody screening or vaccine candidate studies.

Choose nanodiscs for a defined lipid environment.

Nanodiscs provide a smaller and more controlled lipid-bilayer system. They can be valuable for structural biology, biophysical studies and selected ligand-binding experiments.

Choose soluble proteins for routine binding assays.

A soluble extracellular domain is often convenient for ELISA, conventional SPR, BLI and other assays that require easy immobilization and a well-defined analyte.

Choose detergent systems for compatible purified targets.

Detergent micelles can support the extraction and purification of full-length membrane proteins. Success depends on matching the detergent, buffer and downstream assay to the individual target. Researchers can compare Beta LifeScience’s membrane-protein platforms before selecting VLP, nanodisc, detergent or cell-free production.

Catalog VLP or Custom Production?

A catalog VLP is the preferred starting point when the correct target, species and format are already available. It can reduce project setup time and provide access to established product specifications.

Choose a catalog VLP when:

• The required target is already available.
• The listed species matches the study.
• The sequence and format suit the application.
• Existing QC and activity data meet the project needs.
• A standard research quantity is sufficient.

Choose custom VLP production when:

• The target is unavailable in the catalog.
• A different species or sequence is required.
• The project needs an alternative construct.
• A specific tag or labeling strategy is preferred.
• The research requires a particular QC package.
• Larger quantities or continued production are needed.

Beta LifeScience’s Membrane Protein Production in VLPs service can support target evaluation, gene and construct design, VLP production, purification and application-specific validation.

Choosing an Expression Host

Expression-host selection influences VLP assembly, protein folding, glycosylation, yield and scalability. Mammalian cells such as HEK293 or CHO are a strong choice for complex human membrane proteins that require eukaryotic folding, membrane integration and glycosylation. Beta LifeScience primarily uses HEK293 cells for its catalog VLP-displayed transmembrane proteins.

Insect cells can support complex VLP assembly and selected post-translational modifications. Yeast may offer scalable production for compatible self-assembling antigens, while E. coli provides efficient production for suitable structural proteins that do not require mammalian glycosylation. The expression host should be selected according to the antigen structure, required modifications, particle design and downstream application.

Quality Control and Validation

Quality requirements should be defined before starting virus-like particle production. Relevant tests may include:

• Protein identity
• Target expression
• VLP concentration
• Particle size
• Particle homogeneity
• HPLC-based purity assessment
• Endotoxin testing
• Antibody-binding activity
• Formulation and stability
• Lot-specific documentation

Product specifications vary by target and lot. Available VLP products may include HPLC-based purity assessment, controlled endotoxin specifications and product-specific ELISA binding validation. Researchers should review the individual product datasheet or request current lot documentation before ordering.

For custom projects, discuss which methods will be included in the quotation. Beta LifeScience may use BCA to determine VLP concentration and methods such as SEC-HPLC or dynamic light scattering to assess sample content and homogeneity when required.

What to Include in a Custom VLP Inquiry

A complete project brief helps the technical team assess feasibility and recommend an appropriate production strategy. Include:

• Target name and accession number
• Species
• Full-length protein or desired sequence
• Number of transmembrane domains
• Preferred expression host
• Intended application
• Required quantity
• Endotoxin requirement
• Desired purity or homogeneity assessment
• Binding or activity-validation needs
• Buffer and formulation preferences
• Expected project schedule

Need a custom target? Discuss a custom VLP project or request a technical evaluation. Project cost and production time depend on target complexity, expression host, quantity and validation requirements. Request current feasibility, pricing and lead-time information rather than relying on a general estimate.

Ordering VLP Products From Beta LifeScience

For a catalog product, review the product page and submit an inquiry for current availability, pack size, lot documentation and pricing. Custom and bulk-order requests should include the target, required amount and technical specifications.

Beta LifeScience supports:

• Catalog VLP products
• Custom VLP production
• Bulk-order inquiries
• Product and platform selection
• Target-specific construct design
• Activity and quality-control planning
• Technical consultation

Researchers can review the purchasingreview the purchasing process or use Contact & Inquiry to request availability, technical evaluation and a quotation.

FAQs

How much VLP material is needed for immunization?

The required amount depends on the antigen, animal model, number of animals, dose, immunization schedule and planned screening assays. Provide these details when requesting a quotation so the technical team can help estimate the required production quantity.

Can Beta LifeScience produce a target unavailable in the catalog?

Yes. Beta LifeScience offers custom VLP membrane protein production for suitable targets, including GPCRs, claudins, ion channels and other complex membrane proteins.

What QC data are available for a custom VLP project?

Available testing may include concentration, target expression, particle homogeneity, purity, endotoxin and antibody-binding validation. The final QC package should be agreed upon during project evaluation.

Are complete VLPs suitable for SPR or BLI?

Complete VLPs contain a lipid bilayer and are generally unsuitable for conventional SPR or BLI immobilization. A soluble protein or compatible nanodisc format may be more suitable for these assays.

How should I choose between VLPs and nanodiscs?

Choose a VLP for multivalent immunization and antibody screening against native-like membrane targets. Choose a nanodisc when the study requires a smaller, defined lipid environment for structural, biophysical or selected binding applications.

What information is required for a quotation?

Provide the target, species, accession number, sequence, preferred expression host, intended application, quantity, endotoxin requirement and desired QC tests. You can submit these details through Contact & Inquiry.

References

1. Kheirvari M, Liu H, Tumban E. Virus-like particle vaccines and platforms for vaccine development. Viruses. 2023;15(5):1109. Read the article.
2. Mohsen MO, Bachmann MF. Virus-like particle vaccinology, from bench to bedside. Cellular & Molecular Immunology. 2022;19:993–1011. Read the article.
3. Cubas R, Zhang S, Kwon S, et al. Virus-like particle lymphatic trafficking and immune response. Journal of Immunotherapy. 2009;32(2):118–128. Read the article.
4. Urakami A, Sakurai A, Ishikawa M, et al. Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus. Clinical and Vaccine Immunology. 2017;24(7):e00090-17. Read the article.